Trial Profile

Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bifikafusp alfa (Primary)
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Rectal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

30 May 2017 Status changed from discontinued to completed.
22 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
22 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com